A Study to Evaluate the Efficacy and Safety of Glumetinib Combined With Osimertinib Mesylate Versus Platinum-based Doublet Chemotherapy in Non-Small Cell Lung Cancer Patients After Resistance to EGFR-TKIs

NCT06829459 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

350

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-Small Cell Lung Cancer

Interventions

DRUG: Glumetinib
DRUG: Osimertinib mesylate
DRUG: Pemetrexed
DRUG: Cisplatin or carboplatin

Sponsor

Shanghai JMT-Bio Inc.